

M. Sakanaka et al
U.S.S.N. 10/070,209
Page 2

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1-93. (Cancelled).

94. (Currently Amended) A method for treating a mammal suffering from or susceptible to diseases causing apoptosis or apoptosis-like death of cells, except for treatment of immune deficiency, which comprises administering to the mammal a composition comprising ginseng, ginseng extracts, or ginseng components, its metabolites, or salts thereof, whercin doses or dosages of ginseng extracts are adjusted to between 145 pg/kg/day and 1450 µg/kg/day, and those of ginseng components are adjusted to between 1.67 pg/kg/day and 1.67 mg/kg/day.

95-107. (Cancelled).

108. (Previously Presented) The method according to claim 94, wherein the cells are nerve cells or neurons.

109. (Previously Presented) The method according to claim 108, wherein the diseases causing apoptosis or apoptosis-like death of nerve cells or neurons is ccrebral infarction or cerebral apoplexy.

110. (Withdrawn) The mcthod according to claim 108, whercin the diseases causing apoptosis or apoptosis-like death of nerve cells or neurons is edema.

111. (Withdrawn) The method according to claim 108, whercin the edema is ccrebral edema, edema of the brain and nervous tissues or edema of the spinal cord tissuc.

M. Sakanaka et al
U.S.S.N. 10/070,209
Page 3

112 (Withdrawn) The method according to claim 94, wherein the cells are cardiomyocytes, cardiac cells, skin cells or skin keratinocytes.

113. (Withdrawn) The method according to claim 112, wherein the diseases causing apoptosis or apoptosis-like death of cardiomyocytes, cardiac cells skin cells or skin keratinocytes is cardiac disease.

114. (Withdrawn) The method according to claim 112, wherein the diseases causing apoptosis or apoptosis-like death of cardiomyocytes, cardiac cells skin cells or skin keratinocytes is skin senescence.

115-116. (Cancelled).

117. (Currently Amended) The method according to any one of claims 94, 108 and 109+108 to 111, wherein the composition comprises crude saponin fraction and it is administered intravenously in a dose range of 14.5 µg/kg/day to 1450 µg/kg/day.

118. (Currently Amended) The method according to any one of claims 94, 108 and 109+112 to 114, wherein the composition comprises crude saponin fraction and it is administered intravenously in a dose range of 145 pg/kg/day to 145 µg/kg/day.

119. (Currently Amended) The method according to any one of claims 94, 108 and 109+108 to 111, wherein the composition comprises ginsenoside Rb₁ and it is administered intravenously in a dose range of 0.167 µg/kg/day to 1.67 mg/kg/day.

120. (Currently Amended) The method according to any one of claims 94, 108 and 109+112 to 114, wherein the composition comprises ginsenoside Rb₁ and it is administered

M. Sakanaka et al
U.S.S.N. 10/070,209
Page 4

intravenously in a dose range of 1.67pg/kg/day to 1.67mg/kg/day.